Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Isis develops drugs based on antisense technology; the drugs intervene at the RNA level to prevent the production of proteins involved in disease.
Ibis, a division of Isis, exploits its parent’s company knowledge of RNA to develop a biosensor to rapidly and accurately identify infectious organisms including those that could be used in potential biological warfare attacks.
|
Isis’ flagship product is Vitravene, which is based on its antisense technology and it inhibits cells from producing disease-causing proteins, the drug treats cytomegalovirus retinitis, a cause of blindness in AIDS patients. The drug is sold worldwide by its partner Novartis Ophthalmics. Isis has other antisense-based drugs in various stages of development.
Isis division Ibis, has developed the TIGER (Triangulation Identification for Genetic Evaluation of Risks) biosensor system, a revolutionary system to identify infectious organisms.
|